{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T20:22:00Z","timestamp":1769890920684,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bmcl.2025.130494","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:40:55Z","timestamp":1765212055000},"page":"130494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A potent and selective ROR\u03b3 inhibitor for the treatment of autoimmune diseases"],"prefix":"10.1016","volume":"132","author":[{"given":"Taku","family":"Ikenogami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Katsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojo","family":"Arita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Aratsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Thacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Shiozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2025.130494_bb0005","doi-asserted-by":"crossref","DOI":"10.1621\/nrs.07003","article-title":"Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism","volume":"7","author":"Jetten","year":"2009","journal-title":"Nucl Recept Signal"},{"key":"10.1016\/j.bmcl.2025.130494_bb0010","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor ROR\u03b3t directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2025.130494_bb0015","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and Th17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2025.130494_bb0020","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/j.bmcl.2025.130494_bb0025","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1080\/17460441.2021.1948833","article-title":"Retinoic acid-related orphan receptor gamma t (ROR\u03b3t) inverse agonists\/antagonists for the treatment of inflammatory diseases \u2013 where are we presently?","volume":"16","author":"Gege","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.bmcl.2025.130494_bb0030","doi-asserted-by":"crossref","first-page":"13807","DOI":"10.1021\/acs.jmedchem.1c01197","article-title":"AZD0284, a potent, selective, and orally bioavailable inverse agonist of retinoic acid receptor-related orphan receptor C2","volume":"64","author":"Narjes","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130494_bb0035","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1021\/acs.jmedchem.8b00061","volume":"61","author":"Kono","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130494_bb0040","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1021\/acsmedchemlett.0c00575","article-title":"Discovery of a series of Pyrazinone ROR\u03b3 antagonists and identification of the clinical candidate BI 730357","volume":"12","author":"Harcken","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2025.130494_bb0045","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1021\/acs.jmedchem.3c01933","article-title":"Discovery and SAR of JTE-151: a novel ROR\u03b3 inhibitor for clinical development","volume":"67","author":"Maeba","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130494_bb0050","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1021\/acsmedchemlett.5b00253","article-title":"SAR exploration guided by LE and Fsp3: discovery of a selective and orally efficacious ROR\u03b3 inhibitor","volume":"7","author":"Hirata","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2025.130494_bb0055","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1021\/acs.jmedchem.8b01567","article-title":"Discovery of second generation ROR\u03b3 inhibitors composed of an azole scaffold","volume":"62","author":"Kotoku","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130494_bb0060","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2025.130494_bb0065","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/17460441.2.4.469","article-title":"Ligand efficiency indices for effective drug discovery","volume":"2","author":"Abad-Zapatero","year":"2007","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.bmcl.2025.130494_bb0070","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","article-title":"The role of ligand efficiency metrics in drug discovery","volume":"13","author":"Hopkins","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2025.130494_bb0075","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","article-title":"Ligand efficiency: a useful metric for lead selection","volume":"9","author":"Hopkins","year":"2004","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmcl.2025.130494_bb0080","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1021\/jm901241e","article-title":"Escape from flatland: increasing saturation as an approach to improving clinical success","volume":"52","author":"Lovering","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130494_bb0085","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.drudis.2020.07.017","article-title":"Fsp3: A new parameter for drug-likeness","volume":"25","author":"Wei","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmcl.2025.130494_bb0090","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/aps.2016.32","article-title":"Discovery and structural optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-ones as RORc inverse agonists","volume":"37","author":"Wu","year":"2016","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.bmcl.2025.130494_bb0095","series-title":"Modulators of retinoid-related orphan receptor gamma. U.S. Patent US8389739","author":"Thacher","year":"2013"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25004032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25004032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:00:59Z","timestamp":1769835659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25004032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":19,"alternative-id":["S0960894X25004032"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130494","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A potent and selective ROR\u03b3 inhibitor for the treatment of autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130494","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130494"}}